Phenotypes associated with this allele

• Allele Symbol: Col1a1^{tm2(tetO-GFP/RNAi:Smc1a)Iaai}
• Allele Name: targeted mutation 2, Iannis Aifantis
• Allele ID: MGI:5911565
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Col1a1^tm2(tetO-GFP/RNAi:Smc1a)Iaai/Col1a1^+ Gt(ROSA)26Sor^tm1(rtTA*M2)Jae/Gt(ROSA)26Sor^+	involves: 129S4/SvJae * C57BL/6	MGI:5911576
cx2	Col1a1^tm2(tetO-GFP/RNAi:Smc1a)Iaai/Col1a1^tm3(tetO-GFP/RNAi:Stag2)Iaai Gt(ROSA)26Sor^tm1(rtTA*M2)Jae/Gt(ROSA)26Sor^+	involves: 129S4/SvJae * C57BL/6	MGI:5911579

Genotype
MGI:5911576

cx1

• Allelic Composition: Col1a1^{tm2(tetO-GFP/RNAi:Smc1a)Iaai}/Col1a1⁺; Gt(ROSA)26Sor^{tm1(rtTA*M2)Jae}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129S4/SvJae * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

hematopoietic system

enlarged spleen ( J:229031 )

abnormal definitive hematopoiesis ( J:229031 )

• lineage skewing is seen following prolonged doxycycline exposure (30 days)

myeloid metaplasia ( J:229031 )

extramedullary hematopoiesis ( J:229031 )

• in the splenic parenchyma

abnormal bone marrow cell number ( J:229031 )

• decrease in the Ter119+ cell population

increased bone marrow cell number ( J:229031 )

• hypercellular bone marrow with erythroid and megakaryocytic hypoplasia and marked myeloid hyperplasia

increased granulocyte monocyte progenitor cell number ( J:229031 )

• in the GFP+ cells in the bone marrow

increased neutrophil cell number ( J:229031 )

• in peripheral blood of aged mice

decreased B cell number ( J:229031 )

• decrease in the proportion of B cell population (B220+)

increased myeloid cell number ( J:229031 )

• increase in the proportion of myelomonocytic (Cd11b+/Gr1+) and erythroid (CD71+/Ter119+) cells

• increased amount of early erythroid (CD71+/Ter119+) cells in the spleen

myeloid hyperplasia ( J:229031 )

• aged mice show marked expansion of myeloid elements (granulocytic > monocytic) in the peripheral blood

abnormal hematopoietic stem cell morphology ( J:229031 )

• increase in nuclear size in sorted Lineage-/c-Kit+ progenitor cells not associated with an increase of genomic material or instability

decreased hematopoietic stem cell number ( J:229031 )

• decrease in the number of GFP+ cells in the long-term (CD150+) and short-term (CD150-/CD48-) subsets

• compensated for with an increase in the CD150+/CD48+ multipotent progenitor subset

increased hematopoietic stem cell number ( J:229031 )

• in the spleen

increased spleen red pulp amount ( J:229031 )

• in aged mice

immune system

enlarged spleen ( J:229031 )

myeloid hyperplasia ( J:229031 )

• aged mice show marked expansion of myeloid elements (granulocytic > monocytic) in the peripheral blood

myeloid metaplasia ( J:229031 )

increased neutrophil cell number ( J:229031 )

• in peripheral blood of aged mice

decreased B cell number ( J:229031 )

• decrease in the proportion of B cell population (B220+)

increased spleen red pulp amount ( J:229031 )

• in aged mice

growth/size/body

enlarged spleen ( J:229031 )

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
myeloproliferative neoplasm		DOID:2226		J:229031

Genotype
MGI:5911579

cx2

• Allelic Composition: Col1a1^{tm2(tetO-GFP/RNAi:Smc1a)Iaai}/Col1a1^{tm3(tetO-GFP/RNAi:Stag2)Iaai}; Gt(ROSA)26Sor^{tm1(rtTA*M2)Jae}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129S4/SvJae * C57BL/6

hematopoietic system

abnormal definitive hematopoiesis ( J:229031 )

• lineage skewing is seen following short term doxycycline exposure

myeloid hyperplasia ( J:229031 )

• develops over time

anemia ( J:229031 )

• develops over time

decreased B cell number ( J:229031 )

• decrease in the proportion of B cell population (B220+) develops over time

abnormal spleen morphology ( J:229031 )

• disrupted morphology

enlarged spleen ( J:229031 )

• following short term doxycycline exposure

immune system

myeloid hyperplasia ( J:229031 )

• develops over time

decreased B cell number ( J:229031 )

• decrease in the proportion of B cell population (B220+) develops over time

abnormal spleen morphology ( J:229031 )

• disrupted morphology

enlarged spleen ( J:229031 )

• following short term doxycycline exposure

growth/size/body

enlarged spleen ( J:229031 )

• following short term doxycycline exposure